Mannitol 5% Injectable Recalled Due to Sterility Assurance Concerns
The Compounding Pharmacy of America is recalling Mannitol 5% Injectable vials because FDA inspections found GMP violations that may impact sterility.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II and involves a sterile injectable product where GMP violations impact sterility assurance, posing a significant risk of infection or injury.
Plain-English summary
The Compounding Pharmacy of America is recalling Mannitol 5% Injectable, Multi-Dose Vials. The recall involves 425 ml total of the sterile, room-temperature product distributed nationwide between November 2014 and May 2015. Specific lots include 04072015@30 (expiration 7/6/2015) and 05042015@23 (expiration 8/2/2015).
The recall was initiated due to a lack of assurance of sterility. FDA inspections identified Good Manufacturing Practice (GMP) violations that potentially impact the product's quality and sterility. The agency has classified this recall as Class II.
Healthcare providers and patients should stop using the affected Mannitol 5% Injectable vials and contact the recalling firm for further instructions. Consumers should verify lot numbers against the recall notice to determine if their product is affected.
The recalled product
- Product
- Mannitol 5% Injectable, Multi-Dose Vial, Sterile, Room Temperature, The Compounding Pharmacy of America, Knoxville, TN
- Manufacturer
- The Compounding Pharmacy of America
- Category
- Drug — Injectable
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- All lots distributed between November 2014 and May 2015
- 04072015@30
- 7/6/2015
- 05042015@23
- 8/2/2015
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 382 recalled by The Compounding Pharmacy of America under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 382 products in this recall →Related recalls
Same manufacturer · The Compounding Pharmacy of America
See all →- CriticalFDA Recalls Non-Sterile HCG and Methylcobalamin Injection Vials
FDA (Drugs) · 2018-02-21
- SevereFDA Recalls Morphine and Ropivacaine Compounded Solution Due to Sterility Concerns
FDA (Drugs) · 2015-09-23
- SevereHydromorphone Solution Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-09-23
- SevereMorphine and Bupivacaine Solution Recalled for Sterility Concerns
FDA (Drugs) · 2015-09-23
- SevereMethylcobalamin Injectable Recalled for Sterility Assurance Concerns
FDA (Drugs) · 2015-09-23
Same hazard · sterility
See all →- SevereK.C. Pharmaceuticals Recalls Target Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereFDA Recalls Glutathione Injectable Due to Sterility Concerns
FDA (Drugs) · 2013-06-12
- SevereJohn W Hollis Recalls Mannitol 5% Solution for Injection Due to Sterility Concerns
FDA (Drugs) · 2014-06-25
- SevereUS Compounding Recalls Phenylephrine Vials Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-11-25
- SevereFDA Recalls Key Pharmacy Compounded Sterile Injections Due to Sterility Concerns
FDA (Drugs) · 2017-05-24
- SevereB-Complex Injectable Recalled Due to Sterility Concerns
FDA (Drugs) · 2013-06-12
- SevereDexpanthenol Injectable Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2013-06-12